Introduction {#Sec1}
============

The clinical consequences of osteoporosis are mainly the increased incidence of fractures and their associated morbidity and premature mortality. In addition to the negative impact on the quality and quantity of life of the individual, osteoporosis is a costly disease for society. The number of fragility fractures and the societal costs associated with the disease are expected to increase in the future, partly due to changes in demography and improved life expectancy and, in some countries, due to an increase in age-specific incidence of fractures. In 1990, the number of osteoporotic fractures in Europe was estimated to be 2.7 million, with a direct cost of €36 billion, of which €24.3 billion were accounted for by hip fractures. Costs are expected to rise to €76.8 billion by the year 2050 \[[@CR1]\] because of the increasing number of the elderly in the population.

The importance of developing treatments that reduce the risk of fracture is evident, both from an individual and a societal perspective, and a number of agents are available that have been shown in randomised controlled trials to decrease the risk of vertebral and, in some instances, non-vertebral fracture \[[@CR2], [@CR3]\]. Major pharmacological interventions are the bisphosphonates, strontium ranelate, raloxifene, denosumab and parathyroid hormone peptides. Interventions that are approved for the prevention and treatment of osteoporosis in Europe are shown in Table [1](#Tab1){ref-type="table"}. They are approved only for the treatment of postmenopausal osteoporosis, but alendronate, etidronate, risedronate and zoledronic acid are also approved for the prevention and treatment of glucocorticoid-induced osteoporosis \[[@CR4], [@CR5]\] and alendronate, risedronate, zoledronate and teriparatide are approved for the treatment of osteoporosis in men \[[@CR3], [@CR6]\].Table 1Spectrum of anti-fracture efficacy of interventions approved in Europe \[[@CR3]\]Fracture outcomeInterventionVertebralNon-vertebralHipAlendronate+++Ibandronate++^a^NCEDenosumab+++Risedronate+++Zoledronic acid+++Raloxifene+NCENCEStrontium ranelate+++^a^Teriparatide++NCEPTH (1--84)+NCENCE*NCE* no convincing effects. *PTH* recombinant human parathyroid hormone^a^In subsets of patients (post hoc analysis)

All these interventions have been shown to reduce the risk of vertebral fracture when given with calcium and vitamin D supplements. Some have been shown also to reduce the risk of non-vertebral fractures or specifically hip fractures. Of the available options, alendronate, risedronate, zoledronic acid, denosumab and strontium ranelate reduce vertebral, non-vertebral and hip fractures \[[@CR7]--[@CR15]\] (see Table [1](#Tab1){ref-type="table"}). The reduction in vertebral fracture rate has been between 50% and 70% whereas the magnitude of reduction in non-vertebral fracture, where demonstrated, has generally been smaller and in the order of 15--25%. Because of the broader spectrum of anti-fracture efficacy, these agents are generally regarded as preferred options in the prevention of fractures in postmenopausal women. This distinction may be important because once a fracture occurs, the risk of a subsequent fracture at most common sites is increased independently of bone mineral density, and hence, an intervention that covers all major fracture sites is preferable. Notwithstanding, there have been no head-to-head studies with fracture as the primary outcome, so that direct comparison of efficacy between agents is not possible. For this reason, many treatment guidelines did not make a distinction between these agents in terms of any recommendations for their use \[[@CR16]--[@CR21]\].

Impact of generics {#Sec2}
==================

In recent years, the situation has changed markedly because of the advent of generic bisphosphonates with a substantial decrease in price and the impact of this on cost-effectiveness. A pan-European study from 2004 estimated the cost-effectiveness of branded alendronate in nine countries \[[@CR22]\]. In this study alendronate was shown to be cost saving compared to no treatment in women with osteoporosis (with or without previous vertebral fracture) from the Nordic countries (Norway, Sweden and Denmark). The cost-effectiveness of alendronate compared to no treatment was also within acceptable ranges in Belgium, France, Germany, Italy, Spain and the UK. However, with the rapid decline in the price of the generic alendronate, analyses based on a branded drug price have become obsolete and would require an update. For example, in the above-mentioned study, the annual price of branded alendronate varied between €444/year (UK) to €651/year (Denmark). The current drug price for alendronate is less than €300/year in all countries and even as low as €18/year in the UK. Revisiting the analysis using these prices markedly improves the cost-effectiveness of alendronate \[[@CR23], [@CR24]\] because of the decrease in cost (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Impact of price of intervention on cost-effectiveness for a woman from Sweden aged 65 years and a twofold increased risk of fracture is described by the *continuous line*. The *shaded area* approximates the willingness to pay by the National Institute for Health and Clinical Excellence (NICE) in the UK. The *symbols* represent the cost of generic alendronate in several EU counties Assumed RRR=35%; Costs and effects discounted at 3%; Includes cost in added life-years; Source, reference model of the International Osteoporosis Foundation \[[@CR25]\]. For other assumptions, see \[[@CR26]\]

Before the advent of generic bisphosphonates, practice guidelines in the UK did not consider first-line treatment, and recommendations were largely based on the spectrum of activity of the agent and side effects \[[@CR16]--[@CR21], [@CR27]\]. As a consequence of the marked effect of the price of intervention on cost-effectiveness and the relatively stable price of other interventions, practice guidelines in the UK and elsewhere recommend that generic alendronate be viewed as first-line treatment \[[@CR3], [@CR28], [@CR29]\], and generic alendronate now dominates many European markets \[[@CR23]\]. This view, based on cost minimisation, is sustainable provided that cost is reduced without sacrificing effectiveness. This appears not to be the case and may in part represent a failure of the regulatory pathway.

Regulatory background to generics {#Sec3}
=================================

Most health care systems today have to deal with the challenging obligation of limiting and minimising health expenditure. Given the increasing costs of health care, many global initiatives \[[@CR30]\] and national health policies worldwide recommend therapeutic substitution. Therapeutic substitution is the interchange of a less costly drug in place of another treatment, based on the premise that the cheaper version has the same therapeutic effect \[[@CR31]\]. Usually, a generic version of the same drug is developed and used as a strategy to reduce rapidly prescribing costs \[[@CR32], [@CR33]\].

The generic forms of a reference drug are usually marketed after the patent of the branded agent has expired, i.e. after 10 years or more. As defined by the Directive 2001/83/EC of the European Community \[[@CR34]\], a generic drug contains an active component qualitatively and quantitatively identical to the reference drug, but excipients may differ. The reference is the original and innovative agent that has been made available to the market and registered on the basis of a complete registration procedure, with full quality, safety and efficacy data. In contrast, marketing the generic form necessitates only an abridged procedure since it does not concern a new chemical entity. The manufacturer of a generic drug can submit an application for marketing authorisation built on the basis of the information provided by the full marketing procedure of the reference drug and on proving the bioequivalence of the two drugs, generic and reference, as recommended by the European Medicine Agency guideline \[[@CR34]\]. The avoidance of studies of efficacy and safety reduces markedly the development costs permitting price reduction because major development costs are avoided.

Market authorisation of a generic substitute relies heavily on the demonstration of bioequivalence. A bioequivalence study is a randomized clinical study, usually in healthy volunteers, that compares the bioavailability between the test product and a reference product. For oral agents, such as the bisphosphonates, this will include a comparison of absorption (area under the curve, AUC), the rate of absorption (Tmax) and peak concentration (Cmax) based on serum concentration or more usually with the bisphosphonates on cumulative urinary excretion (Ae) (Fig. [2](#Fig2){ref-type="fig"}). Equivalence is inferred when, for both AUC and Cmax, the 90% confidence interval for the ratio of geometric means for test and reference formulations lies within the range of 0.8--1.25 \[[@CR34]\].Fig. 2Mean cumulative urinary excretion of alendronate 70 mg by mouth after the administration of test and reference formulations (*n* = 70) \[redrawn from [@CR61]\]

Branded vs. generic bisphosphonates {#Sec4}
===================================

Gastrointestinal intolerance of amino-bisphosphonates is a well recognised side effect due in part to local effects on the oesophageal or gastric mucosa. Gastrointestinal adverse effects that have been associated with oral bisphosphonates include dysphagia, oesophagitis, stomach ulceration and, more arguably, oesophageal cancer \[[@CR35]--[@CR39]\]. With alendronate, chemical oesophagitis may occur, promoted by an inadequate amount of water when swallowing the pill and failure to remain upright for some time after taking the drug \[[@CR36], [@CR40]\]. These adverse effects are mitigated somewhat by weekly or monthly rather than daily formulations but contribute to the poor adherence associated with the long-term management of patients with osteoporosis \[[@CR41]--[@CR46]\].

Since the introduction of generic bisphosphonates, reports have consistently concluded that adherence is poorer in patients who take generic alendronate than with the original product. In an insurance claims database of upper gastrointestinal tract outcomes in 6,962 patients either on branded or generic alendronate for a minimum of 3 months (10 mg daily), significantly higher discontinuation rates were noted with the generic versions of alendronate as compared to the brand \[[@CR47]\]. Incident rate ratios (IRR) for treatment discontinuation were higher with two generic formulations compared to the proprietary product (IRR, 1.3; 95% CI 1.04--1.63). Adherence (medication possession ratio, \>80%) was higher (IRR, 1.19; 95% CI 1.11--1.27) and the new use of gastric medications (3.4--4.9%) lower with branded than with the generic equivalent (IRR, 0.71; 95% CI 0.53--0.95). Similar findings were reported from a large Canadian claims database \[[@CR48]\] that examined adherence with a weekly dose (70 mg). After adjusting for potential confounding covariates, patients who were started on weekly oral generic alendronate remained at a higher risk of early discontinuation compared to patients initiated with weekly oral branded alendronate (IRR, 2.08; 95% CI 1.89--2.28) (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Kaplan--Meier curves for the risk of early discontinuation during the year following index date (first dispensation of bisphosphonate) \[[@CR48]\] with kind permission from Springer Science + Business Media BV

It might be argued that the introduction of generic alendronate resulted in a widening of the prescription market with the inclusion of patients less motivated to therapy and thus less compliant than formerly. This seems unlikely given that the same phenomenon was noted when patients established on treatment were switched from a branded to generic formulation. Following the introduction of generic alendronate to the Canadian market in July 2005, over 80% of patients were automatically switched from branded to generic alendronate without notification. An increase in the reports of adverse effects prompted a review of the case notes of 301 women with osteoporosis aged 50 years or more who had been established on treatment with alendronate 10 mg daily or 70 mg weekly between 2003 and 2007 \[[@CR49]\]. The rate of adverse events resulting in the discontinuation of treatment was significantly higher after the introduction of generic alendronate than before (5.3/100 vs. 1.2/100 patient-years of exposure; *p* \< 0.001). The majority of adverse events reported were upper gastrointestinal (61%). The higher rates of GI intolerance were associated with more frequent discontinuation of treatment and significant losses of bone mineral density (BMD) at the femoral neck and lumbar spine.

A second retrospective chart review in Germany compared the effects of once weekly branded risedronate or alendronate with generic alendronate on BMD \[[@CR50]\]. Of 186 women with postmenopausal osteoporosis, treated for at least 12 months, there was a significantly higher incidence of gastrointestinal (and other) adverse events in women taking the generic drugs. Significantly smaller increments in BMD at the lumbar spine (*p* \< 0.05) and total hip (*p* \< 0.01) were observed after 1 year in the group receiving generic alendronate compared to those receiving the two branded bisphosphonates.

Thus, the evidence available indicates that many generic formulations are less well tolerated than the proprietary products and that this leads to poorer adherence, in turn associated with a poorer clinical outcome in terms of effectiveness on BMD \[[@CR51]--[@CR53]\] and ultimately in effectiveness on fracture outcomes \[[@CR44], [@CR51], [@CR54]--[@CR56]\].

Because generic drugs in developed markets are shown to be bioequivalent, it might be assumed that the decrease in effectiveness is a result of the poor adherence. There is some evidence that there may be additional effects on drug efficacy. In the case review of Ringe et al. \[[@CR50]\] unequal efficacy of the generic vs. branded alendronate and risedronate was observed in the effect on BMD: significantly lower treatment-induced increases in BMD at the lumbar spine (*p* \< 0.05) and total hip (*p* \< 0.01) were observed after 1 year in the group receiving generic alendronate compared to those receiving the two branded bisphosphonates. In the Canadian survey \[[@CR49]\], generic treatment was stopped because of a decrease in BMD in a significant minority of patients. Whether some generic products have lower efficacy remains an open question, and poor adherence provides a plausible reason for the apparent reduction in the effectiveness of the generic products.

Formulation {#Sec5}
===========

The question arises whether poor tolerance is due to differences in the formulation between the generics and their branded equivalents, and there is evidence to suggest that this is indeed the case. Mean disintegration times have been found to be significantly faster for two generic formulations of alendronate available in Canada compared to branded alendronate (with or without vitamin D) or branded risedronate \[[@CR57]\]. Disintegration rates of several of the generics available in Europe or the USA were similar to those reported for tablets specifically formulated to disintegrate in the mouth (\<30 s) \[[@CR58]--[@CR60]\] (Fig. [4](#Fig4){ref-type="fig"}). Many other studies have confirmed heterogeneous rates of disintegration \[[@CR58]\]. Dissolution rates appear to have much less variability \[[@CR59]--[@CR63]\].Fig. 4Disintegration times in vitro of Fosamax 70-mg tablets (*R*) and ten generic copies from South America \[redrawn from [@CR58]\]

In 2005, Epstein showed a greater irritant response in dogs from a generic alendronate compared to the reference product when tablets of the two formulations were placed at the lower oesophagus: the differences were attributed to the excipients, since the active ingredient (alendronate sodium) and the dose in copy alendronate tablets were similar to branded tablets \[[@CR64]\].

Rapid disintegration with semi-particulate alendronate may cause poor tolerance by adhering to the oesophageal mucosa. Such an effect of a majority of generic formulations of alendronate, but not the proprietary products, was shown in vitro on the oesophageal mucosa of pigs \[[@CR65]\]. All but one of six generics displayed "cleavage" rupture leaving a large piece of tablet strongly adherent to the oesophageal mucosa.

Discussion {#Sec6}
==========

The evidence reviewed suggests that a high proportion of generic formulations of alendronate and possibly other bisphosphonates are associated with poorer tolerance and more frequent and severe adverse events than the proprietary compound. A plausible mechanism lies in the differences in the formulation of the excipients, rather than in the content of active product. The finding of different disintegration profiles and oesophageal bio-adhesiveness supports this view and suggests that the safety profiles of the different marketed tablets might be not be identical. It should be acknowledged that these findings are based on a sample of generic products and that not all generic bisphosphonates should necessarily be tarred with the same brush.

This poses a challenge for regulators in the approval process for generic products with known or suspected upper gastrointestinal toxicity. Marketing authority is usually based on bioequivalence with the presumption of therapeutic equivalence, but this neglects the concerns with safety highlighted in the present review. There is a loophole in the current regulatory requirements for the development of generic agents that exhibit gastrointestinal side effects. We recommend that the approval process for such agents should demand comparative studies of gastrointestinal tolerance and safety in relevant target populations. It is of interest that the Australian agency has recently rejected a generic approval because of uncertainties over safety \[[@CR66]\].

Major consequences of poor tolerance are the impact of side effects in patients that continue medication, poor compliance and persistence and the decreased effectiveness of treatment due to poor compliance and persistence. These have implications for management guidelines and health economic assessment.

Even small relatively modest side effects may have implications for cost-effectiveness if their prevalence is high among those that take the agent concerned. An example is shown in Fig. [5](#Fig5){ref-type="fig"} which shows the cost-effectiveness of intervention as a function of the cost of the agent. The lower line (reproduced in Fig. [1](#Fig1){ref-type="fig"}) is the scenario where the incidence of long-standing side effects is negligible. The upper curve shows the same clinical scenario, but where long-standing intolerance reduces quality of life on average by 1% compared to patients not taking the drug. Under these assumptions, treatments costing up to €450/year are within accepted bounds of cost-effectiveness, but a product with significant side effects would be cost-ineffective even with a drug price tenfold lower at €45/year. In the absence of empirical data, the scenarios are hypothetical, but illustrate the need for such data and, in their absence, suggest that health economic evaluations of generic bisphosphonates \[[@CR22], [@CR24], [@CR28], [@CR67]\] should be cautiously interpreted. Thus, despite firm recommendations to introduce generic medication at treatment initiation or to switch from brands to generic forms of treatment \[[@CR28]\], further health economic analyses with generic specific data are required to confirm the validity of such recommendation and quantify the real gain of substituting generic formulations in place of branded medications.Fig. 5Cost-effectiveness of an agent according to price for a woman from Sweden aged 65 years and a twofold increased risk of fracture. The *shaded area* approximates the willingness to pay by NICE in the UK. The lower slope (*triangles*) assumes no adverse effect of the agent on quality of life, whereas the upper slope (*squares*) assumes a 1% decrease in quality of life due to adverse effects of the agent

The impact of poor adherence (rather than side effects) on cost-effectiveness is a relatively recent field of health economics with the creation of models that capture the elements of adherence \[[@CR22], [@CR68]\]. Poor persistence results in lower costs and lower effectiveness so that the effects move in the same direction and may have marginal impact on the ratio of cost with effectiveness. This, however, neglects the acquisition costs to identify the patient (BMD tests, visits to a physician, etc.) so that cost-effectiveness is adversely affected. The problem is compounded by poor compliance when patients may take their bisphosphonate in a non-fasting state or with calcium-containing liquids. Under these circumstances, the cost remains the same (patients take the drug), but the effectiveness is reduced. When comparing full adherence with partial adherence, the variables that on average had the greatest beneficial effect on the incremental cost-effectiveness included the efficacy of the intervention, drug price, underlying risk of fractures, the fraction of benefit assigned to partial adherence, and fracture-related costs. For example, a 1% increase in drug effect lowered the incremental cost-effectiveness ratio (ICER) by 2.2%, and a 1% increase in the drug price of the high-adherence comparator increased the ICER by 2.7% \[[@CR69]\].

The principal effect of poor adherence is that it leaves large groups of patients untreated, such that the public health objectives of fracture reduction are not met. Interventions that are associated with high adherence have a considerable impact on the number of avoided fractures---a feature that appears questionable in the case of generic bisphosphonates.

This review was developed following a meeting on generic bisphosphonates organised by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) in Paris, December 2010, the findings of which were reviewed at an ESCEO-FROMO Symposium of the IOF-ESCEO European Congress on Osteoporosis and Osteoarthritis in Valencia, March 2011. The Alliance for Better Bone Health (sanofi-aventis and Warner Chilcott) provided an unrestricted educational grant to support scientific activities of ESCEO at the European Congress on Osteoporosis in Valencia in March 2011. This publication summarises the discussions of a meeting organised by ESCEO at that congress, with the topic; Generics versus branded medication in osteoporosis: The Alliance has had no editorial control over this publication.
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